🇺🇸 FDA
Pipeline program

neoadjuvant therapy

MRCTA.ECFAH of FMU[2023]405

Approved other active

Quick answer

neoadjuvant therapy for Hepatocellular Carcinoma Resectable is a Approved program (other) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Hepatocellular Carcinoma Resectable
Phase
Approved
Modality
other
Status
active

Clinical trials